Aortic regurgitation
Conditions
Interventions
Remimazolam group:Remimazolam tosilate injection was administered. Induction regimen: intravenous bolus of 0.15–0.30 mg/kg (adjusted according to patient status), administered as a slow bolus over >30
Etomidate group:Etomidate emulsion for injection was administered. Induction regimen: intravenous bolus of 0.15–0.30 mg/kg (adjusted according to patient status), administered as a slow bolus over >30
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 60 years; 2. ASA physical status class III–IV; 3. Symptomatic aortic regurgitation (moderate or severe); 4. Scheduled to undergo transapical TAVR under general anesthesia.
Exclusion criteria
Exclusion criteria: 1. Patients with concomitant severe aortic stenosis or mitral valve disease; 2. Patients receiving vasoactive agents or mechanical support preoperatively; 3. Patients at risk of difficult airway; 4. Patients with pre-existing end-stage organ failure; 5. Patients who refuse to sign informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The degree of decrease in systolic blood pressure; | — |
Secondary
| Measure | Time frame |
|---|---|
| The degree of decrease in mean arterial pressure; | — |
Countries
China
Contacts
Public ContactPeng Ling
West China Hospital of Sichuan University
Outcome results
None listed